Wire flash
FinanceGSK launches $2.5 billion cost-savings program to fund late-stage clinical studies
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
GSK announced on July 28, 2026, a £1.9 billion (US$2.52 billion) cost-savings program aimed at funding the British drugmaker's late-stage clinical studies. The initiative is part of CEO Luke Miels' strategy to accelerate drug development and restore investor confidence. The program will involve significant cost reductions across the company to redirect resources toward its pipeline of experimental medicines. The announcement was made in London and reported by The Business Times Singapore.
Source report
LONDON — GSK on Tuesday (Jul 28) launched a £1.9 billion (US$2.52 billion) cost-savings programme aimed at funding late-stage clinical studies and accelerating drug development.
The initiative is designed to deliver on CEO Luke Miels' promise of faster drug development and to bolster investor confidence in the British drugmaker.
Key Details:
- Savings Target: £1.9 billion (US$2.52 billion)
- Purpose: Fund late-stage studies and accelerate drug development
- Strategic Goal: Restore investor trust and improve pipeline delivery
Photo: REUTERS
Source
The Business TimesRegional
Part of this Story
GSK launches US$2.5 billion savings drive to boost drug pipeline